Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 5c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Xenon Pharmaceuticals (XENE) PT Lowered to $60 at Needham
• Amneal gets FDA approval for lanreotide injection, launches immediately
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance